Pharmacogenomics in Sri Lanka: a comprehensive systematic review of the research landscape and clinical implications.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-11-14 DOI:10.1080/14622416.2024.2421743

Priyanga Ranasinghe, Hajanthy Jeyapragasam, Sandamini Liyanage, Nirmala Sirisena, Vajira Hw Dissanayake

{"title":"Pharmacogenomics in Sri Lanka: a comprehensive systematic review of the research landscape and clinical implications.","authors":"Priyanga Ranasinghe, Hajanthy Jeyapragasam, Sandamini Liyanage, Nirmala Sirisena, Vajira Hw Dissanayake","doi":"10.1080/14622416.2024.2421743","DOIUrl":null,"url":null,"abstract":"Aim: Pharmacogenomics is emerging in South Asia, including Sri Lanka, with potential to optimize drug therapy and reduce adverse effects. This review evaluates the state of pharmacogenomics research in Sri Lanka, emphasizing population-specific factors to guide future advancements.Materials & methods: A literature search was performed across PubMed/Web-of-Science/SciVerse-Scopus/Embase, and Sri Lanka Journals Online, along with searches for relevant theses in local health repositories/university databases. Studies were categorized into clinical correlational, descriptive or novel assay development studies.Results: Eleven published articles and eight theses were included. One study examined somatic variants (KRAS gene), while all others focused on germline variants. There were two clinical correlational studies: tamoxifen adverse effects and CYP2D6 variants and FTO gene rs9939609 variants and weight gain caused by second-generation antipsychotics. Eight descriptive studies evaluated prevalence of CYP2D6 variants, HLA-B*15:02 allele, KRAS gene mutations and variants related to statin, warfarin and anticancer drug metabolism. Additionally, nine studies developed, validated and tested novel assays for detecting key pharmacogenomically important variants.Conclusion: While pharmacogenomics research in Sri Lanka has made strides, more clinical studies and broader genomic research are needed. Overcoming challenges related to funding, public awareness and regional collaboration is essential to advance personalized medicine and improve therapeutic outcomes in Sri Lanka and South Asia.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"551-567"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2024.2421743","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Pharmacogenomics is emerging in South Asia, including Sri Lanka, with potential to optimize drug therapy and reduce adverse effects. This review evaluates the state of pharmacogenomics research in Sri Lanka, emphasizing population-specific factors to guide future advancements.Materials & methods: A literature search was performed across PubMed/Web-of-Science/SciVerse-Scopus/Embase, and Sri Lanka Journals Online, along with searches for relevant theses in local health repositories/university databases. Studies were categorized into clinical correlational, descriptive or novel assay development studies.Results: Eleven published articles and eight theses were included. One study examined somatic variants (KRAS gene), while all others focused on germline variants. There were two clinical correlational studies: tamoxifen adverse effects and CYP2D6 variants and FTO gene rs9939609 variants and weight gain caused by second-generation antipsychotics. Eight descriptive studies evaluated prevalence of CYP2D6 variants, HLA-B*15:02 allele, KRAS gene mutations and variants related to statin, warfarin and anticancer drug metabolism. Additionally, nine studies developed, validated and tested novel assays for detecting key pharmacogenomically important variants.Conclusion: While pharmacogenomics research in Sri Lanka has made strides, more clinical studies and broader genomic research are needed. Overcoming challenges related to funding, public awareness and regional collaboration is essential to advance personalized medicine and improve therapeutic outcomes in Sri Lanka and South Asia.

查看原文本刊更多论文

斯里兰卡的药物基因组学：对研究现状和临床影响的全面系统回顾。

目的：药物基因组学正在包括斯里兰卡在内的南亚地区兴起，具有优化药物治疗和减少不良反应的潜力。本综述对斯里兰卡的药物基因组学研究现状进行了评估，强调了特定人群的因素，以指导未来的研究进展：在 PubMed/Web-of-Science/SciVerse-Scopus/Embase、斯里兰卡期刊在线和当地卫生资料库/大学数据库中搜索相关论文。研究分为临床相关性研究、描述性研究和新型检测开发研究：结果：共收录了 11 篇已发表的文章和 8 篇论文。其中一篇研究探讨了体细胞变异（KRAS 基因），而其他所有研究都侧重于种系变异。有两项临床相关性研究：他莫昔芬的不良反应与 CYP2D6 变异和 FTO 基因 rs9939609 变异与第二代抗精神病药物导致的体重增加。八项描述性研究评估了 CYP2D6 变异、HLA-B*15:02 等位基因、KRAS 基因突变以及他汀类药物、华法林和抗癌药物代谢相关变异的流行情况。此外，九项研究还开发、验证和测试了用于检测重要药物基因组学变异的新型检测方法：虽然斯里兰卡的药物基因组学研究取得了长足进步，但还需要更多的临床研究和更广泛的基因组研究。要在斯里兰卡和南亚推进个性化医疗并改善治疗效果，克服资金、公众意识和地区合作方面的挑战至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.